Farther Finance Advisors LLC Grows Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Farther Finance Advisors LLC increased its stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 3,541.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 10,196 shares of the company’s stock after acquiring an additional 9,916 shares during the quarter. Farther Finance Advisors LLC’s holdings in Maravai LifeSciences were worth $56,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. JPMorgan Chase & Co. raised its holdings in Maravai LifeSciences by 1,172.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,050,245 shares of the company’s stock valued at $33,658,000 after buying an additional 3,731,924 shares during the period. Point72 DIFC Ltd bought a new position in Maravai LifeSciences during the third quarter valued at $22,108,000. Quantinno Capital Management LP raised its stake in shares of Maravai LifeSciences by 610.2% in the third quarter. Quantinno Capital Management LP now owns 336,527 shares of the company’s stock valued at $2,797,000 after acquiring an additional 289,141 shares during the period. Systematic Financial Management LP lifted its holdings in shares of Maravai LifeSciences by 14.7% in the 3rd quarter. Systematic Financial Management LP now owns 1,612,161 shares of the company’s stock worth $13,397,000 after acquiring an additional 206,499 shares during the last quarter. Finally, Wealthfront Advisers LLC purchased a new position in shares of Maravai LifeSciences during the 4th quarter worth about $1,046,000. 50.25% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Maravai LifeSciences

In related news, General Counsel Kurt Oreshack sold 25,000 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $5.03, for a total transaction of $125,750.00. Following the transaction, the general counsel now directly owns 167,618 shares in the company, valued at approximately $843,118.54. The trade was a 12.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.63% of the company’s stock.

Maravai LifeSciences Price Performance

Shares of NASDAQ MRVI opened at $2.27 on Friday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 9.94 and a current ratio of 10.74. The firm has a fifty day moving average of $3.96 and a 200 day moving average of $5.81. The firm has a market cap of $573.24 million, a PE ratio of -1.38 and a beta of -0.08. Maravai LifeSciences Holdings, Inc. has a one year low of $2.07 and a one year high of $11.56.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on MRVI shares. UBS Group reduced their price target on Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating on the stock in a report on Friday. Robert W. Baird downgraded Maravai LifeSciences from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $9.00 to $3.00 in a research report on Wednesday, February 26th. Bank of America cut their price target on shares of Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, March 3rd. Baird R W lowered shares of Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. Finally, Guggenheim assumed coverage on shares of Maravai LifeSciences in a research note on Thursday, December 19th. They issued a “neutral” rating on the stock. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $8.22.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.